TON - September/October 2014 Vol 7 No 5
Founded in 1922, Trinity Health was organized by the immigrants who settled Northwest North Dakota. Under the auspices of the newly formed Trinity Hospital Association, ground was broken to build a 30-bed hospital. Over the ensuing decades, Trinity expanded its facilities and increased the quality and scope of care. Trinity Health is now recognized as the region’s leading healthcare provider. As a nonprofit, fully integrated healthcare system, the network of more than 200 healthcare providers, hospitals, nursing homes, clinics, and other facilities serves an estimated 12,000 outpatients and 130,000 inpatients each year.
This year, the American Society of Clinical Oncology (ASCO) celebrates the 50th anniversary of its founding. ASCO’s 2014 annual meeting acknowledged the society’s role in the advances made against cancer and presented the latest research and educational information about prevention, detection, and treatment of cancer.
ou may have heard about this gene on the radio or in a news article lately. What’s all the fuss about? On August 7, 2014, the New England Journal of Medicine (NEJM) published an article discussing breast cancer risk in families with mutations in PALB2.
Controversies in treatment-induced alopecia and hair adverse events were brought to the attention of the medical community in a presentation by Mario Lacouture, MD, at the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology 2014 annual meeting.
The addition of goserelin to chemotherapy was shown to preserve ovarian function, fertility, and the ability to have a successful pregnancy in premenopausal women with hormone receptor–negative (HR–) early breast cancer, according to results of the Prevention of Early Menopause Study (POEMS), an international Intergroup trial coordinated by the Southwest Oncology Group.
Pegfilgrastim, which mobilizes white blood cells that fight infection, is indicated by the US Food and Drug Administration for the treatment of cancer patients with nonmyeloid malignancies who are receiving anticancer drugs that are associated with clinically significant febrile neutropenia.
National Breast Cancer Awareness Month (NBCAM) originated in October 1985 when the American Cancer Society (ACS) partnered with the pharmaceutical division of Imperial Chemical Industries, now part of AstraZeneca, to sponsor a weeklong event.
Page 1 of 2
Results 1 - 10 of 15
Results 1 - 10 of 15